In human breast cancer, PTEN is frequently inactivated—reported in up to 30–40% of cases when considering loss of expression, deletions, promoter methylation, or post-transcriptional mechanisms—whereas true mutations are less common (~5–10%). This evidence concerns the gene PTEN and breast cancer.